Pulmozyme ^*

Pulmozyme 2.5 mg/2.5 mL is a sterile, clear inhalation solution of dornase alfa supplied in single-dose ampoules designed for administration using a recommended nebuliser/compressor system. Dornase alfa is a genetically engineered form of human deoxyribonuclease I that works by selectively cleaving extracellular DNA in the thick, viscous mucus characteristic of cystic fibrosis, reducing its viscosity and making it easier to clear from the airways. This action helps improve lung function, supports better airway clearance, and can lower the risk of respiratory tract infections when used as part of a comprehensive cystic fibrosis management plan. Pulmozyme is indicated for pediatric and adult patients with cystic fibrosis aged 5 years and older, particularly those with an FVC (forced vital capacity) of 40 % or greater predicted, although some clinicians may adjust dosing frequency (e.g., twice daily) based on clinical response. Treatment should be continued daily with regular CF therapies such as chest physiotherapy, bronchodilators, and antibiotics; efficacy in patients under 5 years of age or with very advanced lung disease has not been well established. Patients should use each ampoule undiluted, follow proper storage instructions (refrigeration), and consult healthcare professionals about potential side effects and administration details.